Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-010099
Filing Date
2025-05-14
Accepted
2025-05-14 08:01:37
Documents
55
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 504762
2 EX-31.1 ex31-1.htm EX-31.1 20139
3 EX-31.2 ex31-2.htm EX-31.2 20204
4 EX-32.1 ex32-1.htm EX-32.1 8380
5 EX-32.2 ex32-2.htm EX-32.2 8205
  Complete submission text file 0001641172-25-010099.txt   2920879

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE indp-20250331.xsd EX-101.SCH 24839
7 XBRL CALCULATION FILE indp-20250331_cal.xml EX-101.CAL 34013
8 XBRL DEFINITION FILE indp-20250331_def.xml EX-101.DEF 75601
9 XBRL LABEL FILE indp-20250331_lab.xml EX-101.LAB 254629
10 XBRL PRESENTATION FILE indp-20250331_pre.xml EX-101.PRE 199353
57 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 272171
Mailing Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019
Business Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019 (646) 427-2727
Indaptus Therapeutics, Inc. (Filer) CIK: 0001857044 (see all company filings)

EIN.: 863158720 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40652 | Film No.: 25942705
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)